动脉粥样硬化治疗的新思路

摘要
图/表
参考文献(0)
相关文章 (14)

全文: PDF (864 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要动脉粥样硬化作为一种慢性大动脉疾病，由胆固醇积累和随后的血管壁炎症引起，是心肌梗死和脑卒中的重要原因，已成为世界范围内威胁人类健康的主要疾病之一。临床上手术治疗动脉粥样硬化的主要方法包括药物洗脱支架和药物涂层球囊。然而目前这两种技术还存在着各自的缺陷，未能很好地满足医学需求。本文论述了近10年来本课题组在此方向的研究进展，并对动脉粥样硬化治疗技术的前景做出展望。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	万密密1
	2
	赵梓楠1
	2
	李婷1
	2
	毛春1
	2

关键词 ：动脉粥样硬化, 药物洗脱支架, 药物涂层球囊, 研究进展

收稿日期: 2020-12-17

基金资助:国家自然科学基金资助项目（21603105）；江苏省社会发展面上基金资助项目（BE2019744）

作者简介: 万密密（1987—），女，博士，副教授，主要从事生物医用材料相关研究，E-mail：wanmimi@njnu.edu.cn

引用本文:

万密密1,2，赵梓楠1,2，李婷1,2，毛春1,2. 动脉粥样硬化治疗的新思路[J]. 江苏大学学报:医学版, 2021, 31(01): 1-5.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2021/V31/I01/1

［1］Libby P. Mechanisms of acute coronary syndromes and their implications for therapy\[J\]. N Engl J Med, 2013, 368(21): 2004-2013.

［2］Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes\[J\]. J Am Coll Cardiol, 2013, 61(1): 1-11.

［3］Libby P, Pasterkamp G, Crea F, et al. Reassessing the mechanisms of acute coronary syndromes\[J\]. Circ Res, 2019, 124(1): 150-160.

［4］Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10004 patients with surveillance angiography\[J\]. Heart, 2014, 100(2): 153-159.

［5］Giulio GS, David RH Jr. Drugeluting coronary-artery stents\[J\]. N Engl J Med, 2013, 368(3): 254-265.

［6］Dierk S, Susanne S, Jacqueline S, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting\[J\]. J Am Coll Cardiol, 2005, 45(2): 312-315.

［7］Oliver S, Petra D, Schila S, et al.Long-segment SFA stenting—the dark sides: instent restenosis, clinical deterioration, and stent fractures\[J\]. J Endovasc Ther, 2006, 12(6): 676-684.

［8］John RL, Khung Keong Y. The treatment of femoropopliteal in-stent restenosis: back to the future\[J\]. J Am Coll Cardiol, 2012, 59(1): 24-25.

［9］Stephan W, Isabella M, Gabriella De P, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia\[J\]. Circulation, 2001, 104(8): 928-933.

［10］Fineschi M, Carrera A, Pierli C. The hybrid percutaneous coronary intervention with drugeluting stent in combination with bioresorbable vascular scaffolds for the treatment of complex coronary lesions\[J\]. G Ital Cardiol, 2017, 18(9): 21S-23S.

［11］Nasuno T, Tokura M, Kageyama M, et al. The wound healing response after implantation of a drugeluting stent is impaired persistently in the long term\[J\]. Heart Vessels, 2016, 31(6): 985-989.

［12］George CMS, Giulio GS, Dimitris M, et al. Percutaneous coronary interventional strategies for treatment of instent restenosis: a network metaanalysis\[J\]. Lancet, 2015， 386(9994):655-664.

［13］Giacoppo D, Gargiulo G, Aruta P, et al. Treatment strategies for coronary instent restenosis: systematic review and hierarchical Bayesian network metaanalysis of 24 randomised trials and 4880 patients\[J\]. BMJ, 2015, 351: h5392.

［14］Robert AB, Michael J, Fernando A,et al. Drug-coated balloon therapy in coronary and peripheral artery disease\[J\]. Nat Rev Cardiol, 2014, 11(1): 13-23.

［15］Bruno S, Ulrich S, Claudia A, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis\[J\]. Circulation, 2004, 110(7): 810-814.

［16］Nelson V, Sérgio M, Manuel A, et al. Ten-year survi-val of patients undergoing coronary angioplasty with firstgeneration sirolimuselutingstents and baremetal stents\[J\]. Rev Port Cardiol, 2020, 39(11): 639-647.

［17］Sho T, Hiroyuki J, Atsushi S, et al. Drugeluting coronary stents: insights from preclinical and pathology studies\[J\]. Nat Rev Cardiol, 2020,17(1): 37-51.

［18］Saadati S, Westphalen H, Eduok U, et al. Biocompatibility enhancement of hemodialysis membranes using a novel zwitterionic copolymer: Experimental, in situ synchrotron imaging, molecular docking, and clinical inflammatory biomarkers investigations\[J\]. Mater Sci Eng C Mater Biol Appl, 2020, 117: 111301.

［19］He J, Jo YJ, Sun XL, et al. Squarainedyes for photovoltaic and biomedical applications\[J\]. Adv Funct Mater, 2020. doi:10.1002/adfm.202008201.

［20］Wang XB, Miao JJ, Zhao HL, et al. Fabrication of nonbiofouling metal stent and in vitro studies on its hemocompatibility\[J\]. J Biomater Appl, 2013, 29(1): 14-25.

［21］Wang XB, Miao JJ, Shao XB, et al. Zwitterionic hyperbranched polyester functionalized cardiovascular stent and its biocompatibility\[J\]. J Colloid Interface Sci, 2014, 420: 88-96.

［22］Wang XB, Chen XQ, Xing L, et al. Blood compatibility of a new zwitterionic bare metalstent with hyperbranched polymer brushes\[J\]. J Mater Chem B, 2013, 1(38): 5036-5044.

［23］Chen H, Wang XB, Zhou Q, et al. Preparation of vascular endothelial cadherin loaded-amphoteric copolymer decorated coronary stents for anticoagulation and endothelialization\[J\]. Langmuir, 2017, 33(46): 13430-13437.

［24］Zhu TY, Gao WT, Fang D, et al. Bifunctional polymer brush-grafted coronary stent for anticoagulation and endothelialization\[J\]. Mater Sci Eng C Mater Biol Appl, 2020. doi:10.1016/j.msec.2020.111725.

［25］Zhu TY, Zhou M, Gao WT, et al. Coronary stents deco-rated by heparin/NONOate nanoparticles for anticoagulant and endothelialized effects\[J\]. Langmuir, 2020, 36(11): 2901-2910.

［26］Wang Q, Hu SL, Wu YB, et al. Multipledrug delivery from mesoporous coating realizing combination therapy for bare metal stents\[J\]. Langmuir, 2019, 35(8): 3126-3133.

［27］Scheller B, Stoll HP, Sovak M, et al. A novel taxane added to the radiographic contrast agent iopromide inhi-bits in-stent restenosis of porcine coronary arteries\[J\]. Am J Cardiol, 2001, 88(5A): 14G-15G.

［28］Xiong GM, Ang HY, Lin JJ,et al. Materials technology in drug eluting balloons: Current and future perspectives\[J\]. J Control Release, 2016, 239: 92-106.

［29］Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter\[J\]. N Engl J Med, 2006, 355(20): 2113-2124.

［30］DeSilvey DL. Treatment of coronary instent restenosis with a paclitaxel-coated balloon catheter\[J\]. Am J Geriatr Cardiol, 2007, 16(2): 115-116.

［31］Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions 24month results of IN.PACT SFA\[J\]. J Am Coll Cardiol, 2015, 66(21): 2329-2338.

［32］Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKETSMALL 2): an openlabel randomised noninferiority trial\[J\]. Lancet, 2018, 392(10150): 849-856.

［33］Xiong GM, Ang HY, Lin JJ, et al. Materials technology in drug eluting balloons: Current and future perspectives\[J\]. 2016, 239: 92-106.

［34］Rykowska I, Nowak I, Nowak R. Drugeluting stents and balloons—materials,structure designs, and coating techniques: A review\[J\]. Molecules, 2020, 25(20): 4624.

［35］Buszman PP, Tellez A, Afari ME, et al. Tissue uptake, distribution, and healing response after delivery of paclitaxel via secondgeneration iopromidebased balloon coating a comparison with the firstgeneration technology in the iliofemoral porcine model\[J\]. JACC Cardiovasc Interv, 2013, 6(8): 883-890.

［36］Radke PW, Joner M, Joost A, et al.Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipient\[J\]. Euro Intervention, 2011, 7(6): 730-737.

［37］Lamichhane S, Anderson J, Remund T, et al. Dextran sulfate as a drug delivery platform for drugcoated balloons: Preparation, characterization,in vitro drug elution, and smooth muscle cell response\[J\]. J Biomed Mater Res B, 2016, 104(7): 1416-1430.

［38］Anderson JA, Lamichhane S, Vierhout T, et al.In vitro particulate and in vivo drug retention study of a novel polyethylene oxide formulation for drugcoated balloons\[J\]. J Vasc Surg, 2018, 67(5): 1537-1545.

［39］Anderson JA, Lamichhane S, Remund T, et al. Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drugcoated balloons\[J\]. Acta Biomater, 2016, 29: 333-351.

［40］Peters EB, Kibbe MR. Nanomaterials to resolve atherosclerosis\[J\]. ACS Biomater Sci Eng, 2020, 6(7): 3693-3712.

［41］Wan MM, Wang Q, Li XY, et al. Systematic research and evaluation models of nanomotors for cancer combined therapy\[J\]. Angew Chem Int Ed, 2020, 59(34): 14458-14465.

［42］Wan MM, Li T, Chen H, et al. Biosafety, functionalities and applications of biomedical micro/nanomotors\[J\]. Angew Chem Int Ed, 2020. doi:10.1002/anie.202013689.

［43］Wan MM, Chen H, Wang Q, et al. Bioinspired nitrico-xide-driven nanomotor\[J\].Nat Commun, 2019, 10(1): 2323.

［44］Antonio C, Roberto P, Giuseppe V, et al. Targeting inflammation with nanosized drug delivery platforms in cardiovascular diseases: immune cell modulation in atherosclerosis\[J\]. Front Bioeng Biotechnol, 2018, 6: 177-187.

［45］Giulia C, Sophie C, Bart S. Macrophage subsets in atherosclerosis\[J\]. Nat Rev Cardiol, 2015, 12(1): 10-17.

［46］Aldons JL. Atherosclerosis\[J\]. Nature, 2000,407(6801): 233-241.

［47］Koch CD, Lee CM, Apte SS,et al.Aggrecan in cardiovascular development and disease\[J\]. J Histochem Cytochem, 2020, 68(11): 777-795.

［48］Huang YY, Li T, Gao WT, et al. Platelet-derived nanomotor coated balloon for atherosclerosis combination therapy\[J\]. J Mater Chem B, 2020, 8(26): 5765-5775.

［49］Singha S, Shao K, Yang Y, et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices\[J\]. Nat Nanotechnol, 2017, 12(7): 701-710.

［50］Clemente-Casares X, Blanco J, Ambalavanan P, et al. Expanding antigen-specific regulatory networks to treat autoimmunity\[J\]. Nature, 2016, 530(7591): 434-440.

［51］Wan MM, Wan Q, Wang RL, et al. Platelet-derived porous nanomotor for thrombus therapy\[J\]. Sci Adv, 2020, 6(22): eaaz9014.